{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:59:16Z","timestamp":1789750756019,"version":"4.0.1"},"reference-count":108,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Henan Medical Science and Technology Joint Building Program","award":["LHGJ20230899"],"award-info":[{"award-number":["LHGJ20230899"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Breast cancer is the most common malignant tumor among women worldwide, and conventional chemotherapy faces major challenges including poor targeting, severe systemic toxicity, and drug resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review analyzes the application of nano-drug delivery systems (NDDS) in improving breast cancer chemotherapy, with a particular focus on recent advances in nanocarrier-based targeting strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review systematically outlines the current epidemiology and clinical treatment landscape of breast cancer, and provides a detailed analysis of various drug delivery systems (e.g., liposomes, polymeric micelles, inorganic nanoparticles) and their targeting mechanisms, including passive, active, and physicochemical-responsive targeting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NDDS enhance tumor-selective uptake and therapeutic efficacy while reducing side effects, especially active-targeting systems modified with small-molecule ligands such as biotin. Furthermore, NDDS can circumvent multidrug resistance by inhibiting efflux pumps and modulating the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Nano-drug delivery systems represent a promising disease-modifying approach for precise breast cancer treatment, though challenges remain in clinical translation, which may be overcome through interdisciplinary collaboration and systematic optimization.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jpp\/rgag068","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T11:42:05Z","timestamp":1780141325000},"source":"Crossref","is-referenced-by-count":1,"title":["Advances in nano-drug delivery systems for targeting therapy of breast cancer"],"prefix":"10.1093","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7344-9026","authenticated-orcid":false,"given":"Yi","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Translational Medicine Center, The First Affiliated Hospital of Zhengzhou University , Zhengzhou 450052 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Cui","sequence":"additional","affiliation":[{"name":"Zhengzhou Immuno Bio-Tech Co., Ltd , Zhengzhou 450061 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, The First Affiliated Hospital of Henan Polytechnic University (the Second People\u2019s Hospital of Jiaozuo City) , Jiaozuo 454001 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,21]]},"reference":[{"key":"2026062114264473800_ref1","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/jamasurg.2025.2332","article-title":"Recurrence risk in young women with breast cancer","volume":"160","author":"Margenthaler","year":"2025","journal-title":"JAMA Surg"},{"key":"2026062114264473800_ref2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/00031348251331294","article-title":"Breast cancer risk, screening, and risk reduction in young females","volume":"91","author":"Gheller","year":"2025","journal-title":"Am Surg"},{"key":"2026062114264473800_ref3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"Ca-Cancer J Clin"},{"key":"2026062114264473800_ref4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Bingfeng","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"2026062114264473800_ref5","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"2026062114264473800_ref6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1093\/jnci\/89.13.917","article-title":"Multidrug resistance in breast cancer: a meta-analysis of MDR1\/gp170 expression and its possible functional significance","volume":"89","author":"Trock","year":"1997","journal-title":"J Natl Cancer Inst"},{"key":"2026062114264473800_ref7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.canrad.2021.11.013","article-title":"Radiotherapy of breast cancer","volume":"26","author":"Hennequin","year":"2022","journal-title":"Cancer Radiother"},{"key":"2026062114264473800_ref8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/CRD.0000000000000589","article-title":"Cardiotoxicity of breast cancer chemotherapy","volume":"33","author":"Roberts","year":"2025","journal-title":"Cardiol Rev"},{"key":"2026062114264473800_ref9","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.nurpra.2020.10.015","article-title":"Endocrine therapy for breast cancer","volume":"17","author":"Noe","year":"2021","journal-title":"J Nurse Pract"},{"key":"2026062114264473800_ref10","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3390\/biom14101219","article-title":"Molecular targets for breast cancer therapy","volume":"14","author":"Aliabadi","year":"2024","journal-title":"Biomolecules"},{"key":"2026062114264473800_ref11","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.3390\/ijms25147517","article-title":"Immunotherapy in breast cancer","volume":"25","author":"Dvir","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026062114264473800_ref12","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20171357","article-title":"Combined drug therapeutic strategies for the effective treatment of triple negative breast cancer","volume":"38","author":"Chalakur-Ramireddy","year":"2018","journal-title":"Biosci Rep"},{"key":"2026062114264473800_ref13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000194306","article-title":"Evidence-based complementary medicine in breast cancer therapy","volume":"4","author":"Beuth","year":"2009","journal-title":"Breast Care"},{"key":"2026062114264473800_ref14","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1055\/s-0031-1274532","article-title":"Individualized treatment of breast cancer","volume":"136","author":"Eucker","year":"2011","journal-title":"Dtsch Med Wochenschr"},{"key":"2026062114264473800_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.chemphyslip.2020.104882","article-title":"Dual-targeting liposome modified by glutamic hexapeptide and folic acid for bone metastatic breast cancer","volume":"228","author":"","year":"2020","journal-title":"Chem Phys Lipids"},{"key":"2026062114264473800_ref16","doi-asserted-by":"publisher","volume":"223","author":"","DOI":"10.1016\/j.chemphyslip.2019.104785"},{"key":"2026062114264473800_ref17","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ctro.2021.12.010","article-title":"Adjuvant locoregional radiation therapy in breast cancer patients with pathologic complete response after neoadjuvant chemotherapy: a systematic review and meta-analysis","volume":"33","author":"Nikyar","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"key":"2026062114264473800_ref18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1586\/14737140.6.3.427","article-title":"Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions","volume":"6","author":"Dang","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026062114264473800_ref19","first-page":"567","article-title":"Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation","volume":"2","author":"Rahman","year":"2007","journal-title":"Int J Nanomedicine"},{"key":"2026062114264473800_ref20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/128_2007_3","article-title":"Molecular mechanisms of anthracycline activity","volume":"283","author":"Beretta","year":"2008","journal-title":"Top Curr Chem"},{"key":"2026062114264473800_ref21","doi-asserted-by":"publisher","first-page":"1448037","DOI":"10.3389\/fcell.2024.1448037","article-title":"Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer","volume":"12","author":"Shen","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"2026062114264473800_ref22","doi-asserted-by":"publisher","first-page":"e12119","DOI":"10.1200\/JCO.2019.37.15_suppl.e12119","article-title":"Doxorubicin response prediction in neoadjuvant breast cancer therapy","volume":"37","author":"Buhl","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026062114264473800_ref23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12032-015-0686-8","article-title":"Efficacy and safety of pirarubicin plus capecitabine versus pirarubicin plus cyclophosphamide in Chinese node-negative breast cancer patients: a 4-year open-label, randomized, controlled study","volume":"32","author":"Zhang","year":"2015","journal-title":"Med Oncol"},{"key":"2026062114264473800_ref24","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bbcan.2007.10.004","article-title":"Taxanes, microtubules and chemoresistant breast cancer","volume":"1785","author":"McGrogan","year":"2008","journal-title":"Biochim Biophys Acta-Rev Cancer"},{"key":"2026062114264473800_ref25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1200\/jco.2006.24.18_suppl.651","article-title":"Phase II clinical trial of ixabepilone in metastatic breast cancer (MBC) patients previously untreated with taxanes","volume":"24","author":"Denduluri","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026062114264473800_ref26","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.3390\/jpm13101458","article-title":"Breast cancer: clinical-epidemiological profile and toxicities of women receiving treatment with taxanes in the Amazon region","volume":"13","author":"Costa","year":"2023","journal-title":"J Pers Med"},{"key":"2026062114264473800_ref27","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s12094-011-0686-x","article-title":"Efficacy of taxanes as adjuvant treatment of breast cancer: a review and meta-analysis of randomised clinical trials","volume":"13","author":"Gin\u00e9s","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"2026062114264473800_ref28","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s00280-017-3398-2","article-title":"Regulation of paclitaxel activity by microtubule-associated proteins in cancer chemotherapy","volume":"80","author":"Shi","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026062114264473800_ref29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/med.21378","article-title":"Microtubule-binding proteins as promising biomarkers of paclitaxel sensitivity in cancer chemotherapy","volume":"36","author":"Xie","year":"2016","journal-title":"Med Res Rev"},{"key":"2026062114264473800_ref30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3816\/CBC.2010.n.017","article-title":"Evolution of capecitabine dosing in breast cancer","volume":"10","author":"Naughton","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"2026062114264473800_ref31","first-page":"18808","article-title":"Meta-analysis of capecitabine-based chemotherapy versus capecitabine-free chemotherapy in patients with metastatic breast cancer","volume":"9","author":"Zuo","year":"2016","journal-title":"Int J Clin Exp Med"},{"key":"2026062114264473800_ref32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.clbc.2016.05.002","article-title":"Vinorelbine with capecitabine, an evergreen doublet for advanced breast cancer: a systematic literature review and pooled-analysis of phase II-III studies","volume":"16","author":"Petrelli","year":"2016","journal-title":"Clin Breast Cancer"},{"key":"2026062114264473800_ref33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/00000421-200302000-00013","article-title":"Radiation enhancement by gemcitabine-mediated cell cycle modulations","volume":"26","author":"Mose","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"2026062114264473800_ref34","doi-asserted-by":"publisher","first-page":"1702720","DOI":"10.3389\/fcell.2025.1702720","article-title":"Clinical application and drug resistance mechanism of gemcitabine","volume":"13","author":"Zhang","year":"2025","journal-title":"Front Cell Dev Biol"},{"key":"2026062114264473800_ref35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00280-003-0632-x","article-title":"Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study","volume":"52","author":"Donadio","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026062114264473800_ref36","doi-asserted-by":"publisher","first-page":"4327","DOI":"10.1200\/JCO.2007.11.2839","article-title":"Docetaxel plus cyclophosphamide in adjuvant breast cancer","volume":"25","author":"Ferrario","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026062114264473800_ref37","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4149\/neo_2012_005","article-title":"Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane\/anthracycline chemotherapy. Multicenter experience","volume":"59","author":"Ozkan","year":"2012","journal-title":"Neoplasma"},{"key":"2026062114264473800_ref38","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1016\/S0960-9776(17)30270-9","article-title":"A randomized neoadjuvant trial of anthracycline-taxane followed or not followed by cisplatin for HER-2 negative breast cancer","volume":"32","author":"Zhang","year":"2017","journal-title":"Breast"},{"key":"2026062114264473800_ref39","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2165\/00063030-200721020-00001","article-title":"HER-2-positive breast cancer \u2013 hope beyond trastuzumab","volume":"21","author":"Bartsch","year":"2007","journal-title":"BioDrugs"},{"key":"2026062114264473800_ref40","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa053028","article-title":"Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer","volume":"354","author":"Joensuu","year":"2006","journal-title":"N Engl J Med"},{"key":"2026062114264473800_ref41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/000313480407000701","article-title":"Neoadjuvant chemotherapy of breast cancer","volume":"70","author":"Garces","year":"2004","journal-title":"Am Surg"},{"key":"2026062114264473800_ref42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/bjs.4840","article-title":"Neoadjuvant chemotherapy in breast cancer","volume":"92","author":"Charfare","year":"2005","journal-title":"Br J Surg"},{"key":"2026062114264473800_ref43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4143\/crt.2024.1254","article-title":"Adjuvant chemotherapy in breast cancer after neoadjuvant therapy: essential or optional?","volume":"58","author":"Zhang","year":"2026","journal-title":"Cancer Res Treat"},{"key":"2026062114264473800_ref44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s10549-017-4155-2","article-title":"Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients","volume":"163","author":"Goorts","year":"2017","journal-title":"Breast Cancer Res Treat"},{"key":"2026062114264473800_ref45","doi-asserted-by":"publisher","first-page":"98\u2013105","DOI":"10.22514\/ejgo.2023.012","article-title":"GLUT1-mediated magnetic liposomes for targeting bone metastatic breast cancer","volume":"44","author":"","year":"2023","journal-title":"Eur J Gynaecol Oncol"},{"key":"2026062114264473800_ref46","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41598-024-84785-3","article-title":"Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy","volume":"15","author":"Ma","year":"2025","journal-title":"Sci Rep"},{"key":"2026062114264473800_ref47","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.3390\/nu17213352","article-title":"Body composition analysis in postoperative breast cancer patients undergoing chemotherapy and its association with physical activity and quality of life: a longitudinal pilot study","volume":"17","author":"Grupinska","year":"2025","journal-title":"Nutrients"},{"key":"2026062114264473800_ref48","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.2147\/PPA.S168638","article-title":"A qualitative study among breast cancer patients on chemotherapy: experiences and side-effects","volume":"12","author":"Nies","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"2026062114264473800_ref49","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.breast.2015.07.035","article-title":"Long term side effects of adjuvant chemotherapy in patients with early breast cancer","volume":"24","author":"Tao","year":"2015","journal-title":"Breast"},{"key":"2026062114264473800_ref50","doi-asserted-by":"publisher","first-page":"5167","DOI":"10.3390\/curroncol28060433","article-title":"Pegylated liposomal doxorubicin (Caelyx(R)) as adjuvant treatment in early-stage luminal B-like breast cancer: a feasibility phase II trial","volume":"28","author":"Dellapasqua","year":"2021","journal-title":"Curr Oncol"},{"key":"2026062114264473800_ref51","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.2147\/OTT.S105587","article-title":"Onivyde for the therapy of multiple solid tumors","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"2026062114264473800_ref52","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1021\/acs.molpharmaceut.9b01221","article-title":"Albumin nanoparticle of paclitaxel (Abraxane) decreases while taxol increases breast cancer stem cells in treatment of triple negative breast cancer","volume":"17","author":"Yuan","year":"2020","journal-title":"Mol Pharm"},{"key":"2026062114264473800_ref53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ejpb.2017.02.005","article-title":"A glucose-targeted mixed micellar formulation outperforms Genexol in breast cancer cells","volume":"114","author":"Moretton","year":"2017","journal-title":"Eur J Pharm Biopharm"},{"key":"2026062114264473800_ref54","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat Nanotechnol"},{"key":"2026062114264473800_ref55","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1080\/09546630600919993","article-title":"Disseminated classic Kaposi\u2019s sarcoma: two cases with excellent response to pegylated liposomal doxorubicin","volume":"17","author":"Casti\u00f1eiras","year":"2006","journal-title":"J Dermatol Treat"},{"key":"2026062114264473800_ref56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00001813-200303000-00008","article-title":"Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer","volume":"14","author":"Swenson","year":"2003","journal-title":"Anti-Cancer Drugs"},{"key":"2026062114264473800_ref57","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ijhydene.2023.11.237","article-title":"Ultrafine Pd nanoparticles-decorated TiO2 three-dimensional (3D) hybrid aerogel with large specific surface areas and highly interconnected porous networks for hydrogen sensing","volume":"55","author":"Sui","year":"2024","journal-title":"Int J Hydrog Energy"},{"key":"2026062114264473800_ref58","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1021\/acsnano.7b06734","article-title":"Fucoidan prolongs the circulation time of dextran-coated iron oxide nanoparticles","volume":"12","author":"Abdollah","year":"2018","journal-title":"ACS Nano"},{"key":"2026062114264473800_ref59","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1515\/ntrev-2016-0023","article-title":"Application of nanoparticles to reverse multi-drug resistance in cancer","volume":"5","author":"Yang","year":"2016","journal-title":"Nanotechnol Rev"},{"key":"2026062114264473800_ref60","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1177\/0954411915599018","article-title":"Design, analysis and control of a novel tendon-driven magnetic resonance-guided robotic system for minimally invasive breast surgery","volume":"229","author":"Jiang","year":"2015","journal-title":"Proc Inst Mech Eng Part H: J Eng Med"},{"key":"2026062114264473800_ref61","doi-asserted-by":"publisher","first-page":"109057","DOI":"10.1016\/j.bioorg.2025.109057","article-title":"Innovative design and synthesis of dual-acting hCA IX\/CDK-2 inhibitors through hetero ring fused pyrimidine utilization for cutting-edge anticancer therapy: zein nanoparticles for in vivo lung cancer treatment","volume":"166","author":"Abosalim","year":"2025","journal-title":"Bioorg Chem"},{"key":"2026062114264473800_ref62","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40005-025-00731-z","article-title":"Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy","volume":"55","author":"Yuan","year":"2025","journal-title":"J Pharm Investig"},{"key":"2026062114264473800_ref63","doi-asserted-by":"publisher","first-page":"316","DOI":"10.2174\/0929867328666210902141257","article-title":"Gold nanoparticles in triple-negative breast cancer therapeutics","volume":"30","author":"Akter","year":"2023","journal-title":"Curr Med Chem"},{"key":"2026062114264473800_ref64","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1039\/c9tb02711d","article-title":"Glycopolymer decorated multiwalled carbon nanotubes for dual targeted breast cancer therapy","volume":"8","author":"Ozgen","year":"2020","journal-title":"J Mater Chem B"},{"key":"2026062114264473800_ref65","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2174\/1389200223666220514151110","article-title":"Recent advances in nanotechnology-based targeted therapeutics for breast cancer management","volume":"23","author":"Alhalmi","year":"2022","journal-title":"Curr Drug Metab"},{"key":"2026062114264473800_ref66","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.3390\/pr8091022","article-title":"Liposomes: from Bangham to supercritical fluids","volume":"8","author":"Trucillo","year":"2020","journal-title":"Processes"},{"key":"2026062114264473800_ref67","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1080\/10611860802228376","article-title":"Gregory Gregoriadis: introducing liposomes to drug delivery","volume":"16","author":"Perrie","year":"2008","journal-title":"J Drug Target"},{"key":"2026062114264473800_ref68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijpharm.2018.01.039","article-title":"Stable and sustained release liposomal formulations of celecoxib: in vitro and in vivo anti-tumor evaluation","volume":"540","author":"Riahi","year":"2018","journal-title":"Int J Pharm"},{"key":"2026062114264473800_ref69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/1061186X.2025.2534184","article-title":"The enhanced surface permeability and retention effect of topically administrated nanoparticles","volume":"34","author":"Chen","year":"2026","journal-title":"J Drug Target"},{"key":"2026062114264473800_ref70","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ejps.2017.12.011","article-title":"Folic acid-modified liposomal drug delivery strategy for tumor targeting of 5-fluorouracil","volume":"114","author":"Moghimipour","year":"2018","journal-title":"Eur J Pharm Sci"},{"key":"2026062114264473800_ref71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2019.09.018","article-title":"Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release","volume":"315","author":"Aghdam","year":"2019","journal-title":"J Control Release"},{"key":"2026062114264473800_ref72","doi-asserted-by":"publisher","first-page":"20815","DOI":"10.1039\/d5ra02640g","article-title":"Recent advances in nano vehicles encapsulating cinnamic acid and its derivatives as promising anticancer agents","volume":"15","author":"Nabih","year":"2025","journal-title":"RSC Adv"},{"key":"2026062114264473800_ref73","doi-asserted-by":"publisher","first-page":"e44116","DOI":"10.1371\/journal.pone.0044116","article-title":"In vitro and in vivo antitumor activity of a novel pH-activated polymeric drug delivery system for doxorubicin","volume":"7","author":"Huan","year":"2012","journal-title":"PLoS One"},{"key":"2026062114264473800_ref74","doi-asserted-by":"publisher","first-page":"102066","DOI":"10.1016\/j.nano.2019.102066","article-title":"Redox dual-responsive paclitaxel-doxorubicin heterodimeric prodrug self-delivery nanoaggregates for more effective breast cancer synergistic combination chemotherapy","volume":"21","author":"Wang","year":"2019","journal-title":"Nanomedicine"},{"key":"2026062114264473800_ref75","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/ph18071042","article-title":"Matrix metalloproteinase-2-responsive peptide-modified cleavable PEGylated liposomes for paclitaxel delivery","volume":"18","author":"Zhao","year":"2025","journal-title":"Pharmaceuticals"},{"key":"2026062114264473800_ref76","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s13346-024-01669-9","article-title":"Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation","volume":"15","author":"Famta","year":"2025","journal-title":"Drug Deliv Transl Res"},{"key":"2026062114264473800_ref77","doi-asserted-by":"publisher","first-page":"11570","DOI":"10.1038\/s41598-024-62470-9","article-title":"Magnetic resonance imaging of tumor response to stroma-modifying pegvorhyaluronidase alpha (PEGPH20) therapy in early-phase clinical trials","volume":"14","author":"Arias-Lorza","year":"2024","journal-title":"Sci Rep"},{"key":"2026062114264473800_ref78","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1021\/acs.nanolett.6b00820","article-title":"Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy","volume":"16","author":"Zhou","year":"2016","journal-title":"Nano Lett"},{"key":"2026062114264473800_ref79","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1002\/adma.201200454","article-title":"Peptides as targeting elements and tissue penetration devices for nanoparticles","volume":"24","author":"Ruoslahti","year":"2012","journal-title":"Adv Mater"},{"key":"2026062114264473800_ref80","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"2026062114264473800_ref81","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nnano.2011.166","article-title":"Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size","volume":"6","author":"Cabral","year":"2011","journal-title":"Nat Nanotechnol"},{"key":"2026062114264473800_ref82","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2217\/nnm.13.191","article-title":"Shaping cancer nanomedicine: the effect of particle shape on the in vivo journey of nanoparticles","volume":"9","author":"Toy","year":"2014","journal-title":"Nanomedicine (Lond)"},{"key":"2026062114264473800_ref83","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2217\/nnm-2021-0473","article-title":"Ligand-mediated nanomedicines against breast cancer: a review","volume":"17","author":"Picheth","year":"2022","journal-title":"Nanomedicine"},{"key":"2026062114264473800_ref84","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.jinorgbio.2004.07.009","article-title":"Vitamin-mediated targeting as a potential mechanism to increase drug uptake by tumours","volume":"98","author":"Russell-Jones","year":"2004","journal-title":"J Inorg Biochem"},{"key":"2026062114264473800_ref85","doi-asserted-by":"publisher","first-page":"113173","DOI":"10.1039\/c6ra24173e","article-title":"Co-delivery of doxorubicin and the traditional Chinese medicine quercetin using biotin-PEG2000-DSPE modified liposomes for the treatment of multidrug resistant breast cancer","volume":"6","author":"Zhang","year":"2016","journal-title":"RSC Adv"},{"key":"2026062114264473800_ref86","doi-asserted-by":"publisher","first-page":"112204","DOI":"10.1016\/j.ejmech.2020.112204","article-title":"Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer","volume":"193","author":"Tang","year":"2020","journal-title":"Eur J Med Chem"},{"key":"2026062114264473800_ref87","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1039\/c1cs15233e","article-title":"Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment","volume":"41","author":"Walkey","year":"2012","journal-title":"Chem Soc Rev"},{"key":"2026062114264473800_ref88","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/s41467-017-00600-w","article-title":"Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat Commun"},{"key":"2026062114264473800_ref89","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology."},{"key":"2026062114264473800_ref90","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nnano.2012.237","article-title":"Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface","volume":"8","author":"Salvati","year":"2013","journal-title":"Nat Nanotechnol"},{"key":"2026062114264473800_ref91","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae \u2014 the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Control Release"},{"key":"2026062114264473800_ref92","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1200\/JCO.2001.19.5.1444","article-title":"Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin (Myocet) compared with conventional doxorubicin in a randomized trial of metastatic breast cancer","volume":"19","author":"Batist","year":"2001","journal-title":"J Clin Oncol"},{"key":"2026062114264473800_ref93","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"2026062114264473800_ref94","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.3390\/cancers16213657","article-title":"Low-intensity focused ultrasound-responsive phase-transitional liposomes loaded with STING agonist enhances immune activation for breast cancer immunotherapy","volume":"16","author":"Hu","year":"2024","journal-title":"Cancers"},{"key":"2026062114264473800_ref95","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1177\/08853282231162111","article-title":"Liposomal ATM siRNA delivery for enhancing triple-negative breast cancer immune checkpoint blockade therapy","volume":"37","author":"Yu","year":"2023","journal-title":"J Biomater Appl"},{"key":"2026062114264473800_ref96","doi-asserted-by":"publisher","first-page":"104586","DOI":"10.1016\/j.jddst.2023.104586","article-title":"Evaluation of efficacy of tumor-specific nanoliposomal radiosensitizer in radiotherapy","volume":"86","author":"Karabuga","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"2026062114264473800_ref97","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejca.2022.04.038","article-title":"Practice changing data and emerging concepts from recent radiation therapy randomised clinical trials","volume":"171","author":"Espenel","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026062114264473800_ref98","doi-asserted-by":"publisher","first-page":"102834","DOI":"10.1016\/j.nano.2025.102834","article-title":"A novel theranostic system of PD-L1-aptamer-functionalized fluorescent silica nanoparticles for triple-negative breast cancer","volume":"68","author":"Tan","year":"2025","journal-title":"Nanomedicine"},{"key":"2026062114264473800_ref99","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00066-003-1150-9","article-title":"Endogenous markers of tumor hypoxia - predictors of clinical radiation resistance?","volume":"179","author":"Vordermark","year":"2003","journal-title":"Strahlenther Onkol"},{"key":"2026062114264473800_ref100","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1126\/science.1114397","article-title":"Toxic potential of materials at the nanolevel","volume":"311","author":"Nel","year":"2006","journal-title":"Science."},{"key":"2026062114264473800_ref101","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1289\/ehp.7339","article-title":"Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles","volume":"113","author":"Oberd\u00f6rster","year":"2005","journal-title":"Environ Health Perspect"},{"key":"2026062114264473800_ref102","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/j.addr.2005.09.019","article-title":"Dendrimer biocompatibility and toxicity","volume":"57","author":"Duncan","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"2026062114264473800_ref103","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s13346-013-0176-5","article-title":"Questioning the use of PEGylation for drug delivery","volume":"3","author":"Verhoef","year":"2013","journal-title":"Drug Deliv Transl Res"},{"key":"2026062114264473800_ref104","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J Control Release"},{"key":"2026062114264473800_ref105","doi-asserted-by":"publisher","DOI":"10.31838\/ijpr\/2020.12.03.367","article-title":"An in vitro evaluation of the ability of ozone nano-bubble water to kill pathogenic Gram-negative and Gram-positive bacteria","volume":"12","author":"Osman","year":"2020","journal-title":"J Pharm Res"},{"key":"2026062114264473800_ref106","doi-asserted-by":"publisher","first-page":"100168","DOI":"10.1016\/j.ailsci.2026.100168","article-title":"Reprogramming cancer therapeutics through artificial intelligence-guided drug repurposing: computational innovation, experimental validation, and translational challenges","volume":"9","author":"Fawzy","year":"2026","journal-title":"Artif Intell Life Sci"},{"key":"2026062114264473800_ref107","doi-asserted-by":"publisher","first-page":"235","DOI":"10.14744\/ejmo.2024.45903","article-title":"The application of artificial intelligence in breast cancer","volume":"8","author":"Nafiss","year":"2024","journal-title":"Eurasian J Med Oncol"},{"key":"2026062114264473800_ref108","doi-asserted-by":"publisher","first-page":"108557","DOI":"10.1016\/j.cclet.2023.108557","article-title":"Harnessing bacteria for tumor therapy: current advances and challenges","volume":"35","author":"Guo","year":"2024","journal-title":"Chin Chem Lett"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/6\/rgag068\/68567498\/rgag068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/78\/6\/rgag068\/68567498\/rgag068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T18:26:52Z","timestamp":1782066412000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/doi\/10.1093\/jpp\/rgag068\/8712785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":108,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgag068","relation":{},"ISSN":["2042-7158"],"issn-type":[{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,6]]},"article-number":"rgag068"}}